Oligodendrocyte-Targeted Adeno-Associated Virus Gene Therapy for Canavan Disease in Children: A Phase I/II Trial

This open-label phase I/II clinical study used a novel recombinant vector, rAAV-Olig001, with selective tropism for oligodendrocytes, to deliver gene therapy for Canavan disease.